Abstract
Objective To observe the clinical effect of preoperative intravitreal injection of Lucentis combined with 23G vitrectomy in the treatment of patients with proliferative diabetic retinopathy. Methods 126 patients with proliferative diabetic retinopathy scheduled for 23G vitrectomy in our hospital from January 2014 to September 2016 were randomly divided into control group and observation group, 63 cases in each group. The control group received 23G vitrectomy, and the observation group received intravitreal injection of Lucentis 7 days before 23G vitrectomy. The operative time, intraoperative bleeding rate, the incidence of iatrogenic retinal breaks, and the intraoperative filling rate of the two groups were compared. All patients were followed up for 2 months, after 2 months visual acuity, vitreous hemorrhage and re-proliferation rates of the two groups were compared. Results Compared with the control group, the operation time, intraoperative bleeding rate, the incidence of iatrogenic retinal breaks of the observation group were significantly reduced (P 0.05). After followed up for 2 months, the incidence of vitreous re-proliferation and hemorrhage of the observation group were significantly lower than those of the control group (P 0.05). Conclusion Intravitreal injection of Lucentis before 23G vitrectomy in the treatment of patients with proliferative diabetic retinopathy can reduce the operation time and the bleeding, improve the visual acuity of the patients. Key words: Lucentis; Vitrectomy; Diabetic retinopathy; Clinical efficacy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have